Navigation » List of Schools » International College of Health Sciences » Nursing » Nursing 1141- Pharmacology » Fall 2022 » Mastery EAQ Ch. 34
Below are the questions for the exam with the choices of answers:
Question #1
A Strong contractions
B Decreased pain
C Midline fundus
D Softened cervix
Question #2
A Pulmonary embolism
B Abnormal vaginal bleeding
C Renal failure
D Ovarian failure
Question #3
A Hirsutism, Bradycardia, Increased diuresis
B Anxiety, Dizziness, Blurred vision
C Blurred vision, Bradycardia, Increased diuresis
D Hirsutism, Dizziness,, Increased diuresis
Question #4
A For at least 6 weeks, starting at the end of the antibiotic regimen
B During the entire period the patient is taking the antibiotic
C Until three throat cultures have been negative for the pathogen
D For at least 1 month after starting the antibiotic
Question #5
A Megestrol
B Alendronate
C Estradiol
D Methylergonovine
Question #6
A Protamine sulfate
B Atropine
C Epinephrine
D Calcium gluconate
Question #7
A Obtain a prescription for terbutaline.
B Obtain a prescription for indomethacin.
C Decrease the drug dose immediately.
D Request a prescription to give calcium gluconate.
Question #8
A Place the patient on her left side.
B Administer phentolamine mesylate.
C Immediately discontinue intravenous (IV) fluids.
D Instruct the patient to bear down and push.
Question #9
A Monitor the patient for blurred vision. Administer it before placenta delivery. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.
B Monitor the patient for blurred vision. Monitor blood pressure during administration. Administer it before placenta delivery. Question the prescription if the patient has liver disease.
C Administer it before placenta delivery. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.
D Monitor the patient for blurred vision. Monitor blood pressure during administration. Assess for pelvic inflammatory disease. Question the prescription if the patient has liver disease.
Question #10
A Pelvic inflammatory disease
B Hypertension
C Nausea and vomiting
D Uterine atony
Question #11
A Temperature
B Blood glucose
C Blood pressure
D Uterine contractions
Question #12
A Absence of cervical ripening at 42 weeks’ gestation
B Vaginal bleeding at 38 weeks’ gestation
C Radiographic confirmation of cephalopelvic disproportion
D Ineffective contractions in a full-term pregnancy
Question #13
A Low fluid intake
B Cigarette use
C Use of herbal supplements
D Current tricyclic antidepressant use
Question #14
A Fetal movement, Uterine hyperactivity, Complete blood cell count
B Fetal heart rate, Fetal movement, The patient’s blood pressure and pulse
C Uterine hyperactivity, Fetal heart rate, Complete blood cell count
D The patient’s blood pressure and pulse, Complete blood cell count, Uterine hyperactivity
Question #15
A Denosumab
B Calcitonin
C Ibandronate
D Tamoxifen
Question #16
A Ask the patient to include soy in her diet.
B Advise the patient to engage in quiet activities.
C Persuade the patient to start the therapy.
D Inform the patient about the benefits and risks of the therapy.
Question #17
A “The treatment is likely to cause endometrial cancer.”
B “You may need to stop smoking during the therapy.”
C “The treatment should be started as soon as possible.”
D “The therapy may cause thromboembolic events.”
Question #18
A Terbutaline
B Ritodrine
C Magnesium sulfate
D Bed rest and hydration
Question #19
A Hypertension
B Anticonvulsant therapy
C Diabetes
D Antibiotic therapy
Question #20
A Norethindrone and ethinyl estradiol
B Male condom with spermicidal jelly
C Medroxyprogesterone
D Cervical cap with spermicidal jelly
Question #21
A Allergy to salmon
B Current smoker
C Joint pain
D Breast cancer
Question #22
A “Replace the bisphosphonate with calcitonin.”
B “Discontinue the calcium supplement.”
C “Space the medications 1 to 2 hours apart.”
D “Obtain a prescription for increasing the bisphosphonate dose.”
Question #23
A “Have tests for serum cholesterol.”
B “Report missed menstrual periods.”
C “Perform weight-bearing exercise.”
D “Have a yearly mammogram.”
Question #24
A “Decreased Gn-RH suppresses the release of follicle-stimulating hormone.”
B “Estrogen levels inhibit the release of follicle-stimulating hormone.”
C “High progesterone levels inhibit the release of luteinizing hormone.”
D “Surges of Gn-RH, follicle-stimulating hormone, and luteinizing hormone stimulate ovulation.”
Question #25
A “I am no longer experiencing painful intercourse.”
B “I no longer experience hot flashes.”
C “I have seen a great improvement in my sexual desire.”
D “I have not experienced any uterine bleeding.”
Question #26
A Ferritin
B Levothyroxine
C Amoxicillin
D Metformin
Question #27
A Contains estrogen, which stimulates bone reabsorption
B Stimulates estrogen receptors on the bone to increase bone density
C Promotes bone absorption of calcium
D Inhibits osteoclast-mediated bone reabsorption
Question #28
A Warfarin, Cholestyramine
B Levothyroxine, Multivitamin
C Atenolol, Levothyroxine
D Multivitamin, Atenolol
Question #29
A “I need to take this medication with food to prevent damage to my esophagus.”
B “I will take the medication on an empty stomach and not lie down for 30 minutes.”
C “I need to decrease my intake of dairy products to prevent hypercalcemia.”
D “This medication will help relieve the bone pain I have from my osteoporosis.”
Question #30
A Hot flashes, Loss of appetite, Joint pain
B Hot flashes, Vertigo, Loss of appetite
C Chest pain, Hot flashes, Loss of appetite
D Vertigo, Joint pain, Chest pain
Question #31
A To induce cervical ripening
B To treat pelvic inflammatory disease
C To terminate pregnancy
D To treat gestational hypertension
Question #32
A Smoking heavily every day
B Sedentary lifestyle
C Consumption of saturated fats
D Increased body mass index (BMI)
Question #33
A Monotherapy with a progestin increases breast cancer risk.
B Unopposed estrogen increases the risk of endometrial cancer.
C Estrogen monotherapy increases the risk of breast cancer.
D Estradiol with progestin increases the risk of endometrial cancer.
Question #34
A Prostaglandin E
B Clomiphene
C Oxytocin
D Terbutaline
Question #35
A Megestrol
B Estropipate
C Estrone
D Medroxyprogesterone
Question #36
A Hot flashes
B Brown discoloration of face
C Yellow undertone to the skin
D Loss of hair
Question #37
A Suggest the patient take aluminum hydroxide with the medication.
B Monitor the patient’s blood pressure frequently.
C Assess pulse oximetry continuously.
D Administer acetaminophen as needed.
Question #38
A Oxytocin
B Indomethacin
C Dinoprostone
D Clomiphene
Question #39
A Ethinyl estradiol
B Clomiphene
C Progesterone
D Choriogonadotropin alfa
Question #40
A Uterine bleeding
B Deep vein thrombosis
C Weight loss
D Dysmenorrhea
Question #41
A “Vaginal cancer is prevented by adding progestin to the regimen.”
B “The progestin in the regimen will help prevent ovarian cancer.”
C “The progestin in the regimen will help prevent breast cancer.”
D “Endometrial cancer risk can be reduced by adding progestin.”
Question #42
A Diminished endometrial tissue proliferation
B Inhibition of the release of gonadotropins
C Elevated progesterone levels inhibiting the release of the luteinizing hormone
D Interference with the proliferation of the fertilized ovum
Question #43
A Luteinizing hormone
B Follicle-stimulating hormone
C Antidiuretic hormone
D Adrenocorticotropic hormone
Question #44
A Hypertension
B Dysmenorrhea
C Weight gain
D Thrombophlebitis
Question #45
A Higher-pitched voice
B Dry skin
C Nausea
D Weight loss
Question #46
A Postpartum hemorrhage
B Termination of pregnancy
C Premature labor
D Accelerated labor
Question #47
A Esterified estrogens
B Alendronate
C Medroxyprogesterone
D Megestrol
Question #48
A Phase 4
B Phase 3
C Phase 2
D Phase 1
Question #49
A Biphasic
B Monophasic
C Triphasic
D Extended-cycle
Question #50
A Follicle-stimulating hormone (FSH)
B Luteinizing hormone (LH)
C Luteotropic hormone
D Interstitial cell-stimulating hormone
Question #51
A Indomethacin
B Megestrol
C Methylergonovine
D Medroxyprogesterone acetate
Question #52
A Methylergonovine
B Terbutaline
C Oxytocin
D Magnesium sulfate
Question #53
A Raloxifene
B Megestrol
C Methylergonovine
D Clomiphene
Question #54
A Day 14
B Day 3
C Day 7
D Day 21
Question #55
A Adrenocorticotropic hormone
B Luteinizing hormone (LH)
C Follicle-stimulating hormone (FSH)
D Antidiuretic hormone
Question #56
A The patient is ready for delivery.
B The contractions can be fatal to the patient.
C The fetal heart rate is stable.
D The patient’s blood pressure is stable.
Question #57
A Compliance with the fertility drugs
B Presence of abnormal uterine bleeding
C Current smoking status
D Current use of medications for depression
Question #58
A Dementia, Ovarian cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events
B Dementia, Breast cancer, Ovarian cancer, Cardiovascular disease, Serious cardiovascular events
C Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Ovarian cancer
D Dementia, Breast cancer, Cigarette smoking, Cardiovascular disease, Serious cardiovascular events